This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Adams, E. R. Articles by Pizzorno, G. Search for Related Content PubMed PubMed Citation Articles by Adams, E. R. Articles by Pizzorno, G.

In Vivo Effect of 5-Ethynyluracil on 5-Fluorouracil Metabolism Determined by ¹⁹F Nuclear Magnetic Resonance Spectroscopy

Yale University School of Medicine, Department of Internal Medicine, Section of Medical Oncology, New Haven, Connecticut 06520 [E. R. A., J. J. L., D. J. C., G. P.], and Glaxo Wellcome, Research Triangle Park, North Carolina 27709 [T. S.]

Biochemical modulation of 5-fluorouracil (5-FU) has been used over the past 20 years to improve the therapeutic efficacy of this antineoplastic agent. Recently, modulation of the catabolic pathway of this fluoropy-rimidine has been the focus of extensive preclinical and clinical investigation. Dihydropyrimidine dehydrogenase catalyzes the rate-limiting step in the catabolism of 5-FU and rapidly degrades 60–90% of the drug. An irreversible inactivating inhibitor of this enzyme, 5-ethynyluracil (EU), markedly improves the antitumor effect of 5-FU in animal models. Early clinical studies have shown a substantial alteration of the systemic disposition of 5-FU with an increase in 5-FU terminal half-life and have also indicated that EU allows safe oral administration of 5-FU by improving the oral bioavailability of the fluoropyrimidine, which is otherwise too erratic and unpredictable for a drug with such a limited therapeutic window.

We evaluated the effect of EU on the metabolism of 5-FU in mice bearing colon 38 tumors using ¹⁹F nuclear magnetic resonance spectroscopy. Ex vivo measurements of tissue extracts from liver, kidney, and tumor indicated a >95% elimination of -fluoro-ß-ureidopropionic acid and -fluoro-ß-alanine signals in the tissues of mice that received 2 mg/kg of EU before administration of 5-FU. The spectra also showed an increased formation of fluoronucleotides in both normal and tumor tissues, a prolonged presence of 5-FU, and the accumulation of 5-fluorouridine that otherwise is undetectable, particularly in normal tissues. The in vivo NMR experiments on colon 38 tumors confirmed these findings, showing a complete elimination of the -fluoro-ß-ureidopropionic acid and -fluoro-ß-alanine signals in tumors treated with EU and a dramatic formation and accumulation of 5-fluorouridine mono-, di-, and triphosphates and 5-fluorouridine. Thus, by inactivating dihydropyrimidine dehydrogenase, EU prolonged the half-life for 5-FU, almost completely eliminated its catabolism for 4–6 h, which led to an increased accumulation of 5-fluorouridine mono-, di-, and triphosphates in both normal and tumor tissues.

This article has been cited by other articles:

				B. Keith, X.-D. Guo, S. Zentko, N. Harold, B. Schuler, M. Quinn, J. Shapiro, and J. L. Grem Impact of Two Weekly Schedules of Oral Eniluracil Given with Fluorouracil and Leucovorin on the Duration of Dihydropyrimidine Dehydrogenase Inhibition Clin. Cancer Res., May 1, 2002; 8(5): 1045 - 1050. [Abstract] [Full Text] [PDF]

				E. O. Aboagye, A. Saleem, V. J. Cunningham, S. Osman, and P. M. Price Extraction of 5-Fluorouracil by Tumor and Liver: A Noninvasive Positron Emission Tomography Study of Patients with Gastrointestinal Cancer Cancer Res., July 1, 2001; 61(13): 4937 - 4941. [Abstract] [Full Text] [PDF]

				J. L. Grem, N. Harold, J. Shapiro, D.-Q. Bi, M. G. Quinn, S. Zentko, B. Keith, J. M. Hamilton, B. P. Monahan, S. Donavan, et al. Phase I and Pharmacokinetic Trial of Weekly Oral Fluorouracil Given With Eniluracil and Low-Dose Leucovorin to Patients With Solid Tumors J. Clin. Oncol., December 1, 2000; 18(23): 3952 - 3963. [Abstract] [Full Text] [PDF]

				J. R. Bading, M. M. Alauddin, J. D. Fissekis, A. H. Shahinian, J. Joung, T. Spector, and P. S. Conti Blocking Catabolism with Eniluracil Enhances PET Studies of 5-[18F]Fluorouracil Pharmacokinetics J. Nucl. Med., October 1, 2000; 41(10): 1714 - 1724. [Abstract] [Full Text] [PDF]

				T. J. Tewson Enzyme Inhibition as an Aid to Simplify Pharmacokinetic Measurements? J. Nucl. Med., October 1, 2000; 41(10): 1725 - 1726. [Full Text] [PDF]

				D. A. Kooby, K. L. Zakian, S. N. Challa, C. Matei, H. Petrowsky, H.-H. Yoo, J. A. Koutcher, and Y. Fong Use of Phosphorous-31 Nuclear Magnetic Resonance Spectroscopy to Determine Safe Timing of Chemotherapy after Hepatic Resection Cancer Res., July 1, 2000; 60(14): 3800 - 3806. [Abstract] [Full Text]

				S. D. Baker, R. B. Diasio, S. O’Reilly, V. S. Lucas, S. P. Khor, S. E. Sartorius, R. C. Donehower, L. B. Grochow, T. Spector, J. A. Hohneker, et al. Phase I and Pharmacologic Study of Oral Fluorouracil on a Chronic Daily Schedule in Combination With the Dihydropyrimidine Dehydrogenase Inactivator Eniluracil J. Clin. Oncol., February 14, 2000; 18(4): 915 - 915. [Abstract] [Full Text] [PDF]

				R. B. Diasio and M. R. Johnson Dihydropyrimidine Dehydrogenase: Its Role in 5-Fluorouracil Clinical Toxicity and Tumor Resistance Clin. Cancer Res., October 1, 1999; 5(10): 2672 - 2673. [Full Text] [PDF]